Our current data describe how Antp-TPR has the molecular features of a novel class of global Hsp90 inhibitor, which is capable of simultaneously disabling the multiple pools of client proteins to increase the erUPR in cancer cells. This evidence concerns the gene HOXA7 and cancer.